Healthed Going Viral Podcast featuring A/Prof Nigel Crawford
MVEC’s Associate Professor Nigel Crawford delivered the COVID-19 Update as part of the recent Healthed Australia online lecture series.
In this lecture, A/Prof Nigel Crawford discussed the following:
- COVID booster dose
- Myocarditis following mRNA vaccine
- Vaccinating 5-11-year-olds with Pfizer
- Best vaccine delivery method
- Opening the borders – don’t forget there are many vaccine-preventable diseases (VPDs)
To listen to the lecture in full, click on the link below:
Healthed lecture series 11 November: COVID-19 Update
The Conversation: Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccination
The COVID-19 pandemic has perpetuated rapid medical advancements and technological innovations. Over the last 20 months, we’ve experienced an influx of new vaccines which have proven to be safe and effective in preventing disease.
Scientists and researchers around the world are already working on the next generation of COVID vaccines to help tackle issues regarding waning immunity, storage and delivery, and vaccine hesitancy. Focusing their efforts on making vaccination easier, delivering more durable immunity and protecting against future variants
This article looks at the different considerations for research and technology around the world that will in turn lead to the next generation of COVID vaccines.
Follow the link to read the full article: Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccination
There's still time to register for the Clinical Vaccinology Update (CVU) 2021!
There's still time to register for the Clinical Vaccinology Update (CVU) 2021 taking place virtually on Thursday 18th and Friday 19th November.
This 2-day virtual program will allow participants to choose from keynote sessions delivered on our virtual main stage in addition to themed seminars and interactive workshops hosted by industry experts, addressing the most important issues in immunisation.
कार्यक्रम के बारे में और जानने के लिए और रजिस्टर करने के लिए, कृपया हमारे ईवेंट पेज के नीचे दिए गए लिंक पर क्लिक करें।
MVEC: Clinical Vaccinology Update (CVU) 2021
मॉडर्न का COVID-19 वैक्सीन (SPIKEVAX) - मूल्यांकन के तहत वयस्कों के लिए बच्चों और बूस्टर शॉट में प्रस्तावित उपयोग के लिए अस्थायी निर्धारण
थेराप्यूटिक गुड्स एडमिनिस्ट्रेशन (TGA) ने मॉडर्न ऑस्ट्रेलिया Pty Ltd को उसके COVID-19 वैक्सीन, SPIKEVAX के संबंध में अनंतिम निर्धारण प्रदान किया है।
SPIKEVAX को 12 वर्ष या उससे अधिक आयु के व्यक्तियों में उपयोग के लिए अस्थायी रूप से अनुमोदित किया गया है। इस दृढ़ संकल्प को प्रदान करने का अर्थ है कि मॉडर्न ऑस्ट्रेलिया प्राइवेट लिमिटेड छोटे बच्चों में उपयोग के लिए टीके के अनंतिम अनुमोदन को बदलने के लिए आवेदन करने के लिए पात्र है।
अधिक पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
मॉडर्न का COVID-19 वैक्सीन (SPIKEVAX) - मूल्यांकन के तहत वयस्कों के लिए बच्चों और बूस्टर शॉट में प्रस्तावित उपयोग के लिए अस्थायी निर्धारण
New immunisation reference page: COVID-19 vaccine compensation scheme
The No Fault COVID-19 Indemnity Scheme is a Commonwealth government funded initiative that has been introduced to allow Australians who have been significantly impacted by an adverse event following a COVID-19 vaccine to apply for financial assistance.
Our new reference page outlines the No Fault COVID-19 Indemnity Scheme, including which vaccines are covered under the scheme, and how to make a claim.
अधिक पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
MVEC: COVID-19 vaccine compensation scheme
Reminder to register for the Clinical Vaccinology Update (CVU) 2021!
A reminder to register for the Clinical Vaccinology Update (CVU) 2021 taking place virtually on Thursday 18th and Friday 19th November.
This 2-day virtual program will allow participants to choose from keynote sessions delivered on our virtual main stage in addition to themed seminars and interactive workshops hosted by industry experts, addressing the most important issues in immunisation.
कार्यक्रम के बारे में और जानने के लिए और रजिस्टर करने के लिए, कृपया हमारे ईवेंट पेज के नीचे दिए गए लिंक पर क्लिक करें।
MVEC: Clinical Vaccinology Update (CVU) 2021
The Conversation: COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far
This week, the US Food and Drug Administration (FDA) has authorised the provisional use of the Pfizer COVID-19 vaccine in children between the age of 5 to 11 years. Children will receive two doses of the vaccine, at a reduced dose (one-third of the adult dose) administered approximately three weeks apart.
Pfizer has submitted a partial application to Australia’s Therapeutic Goods Administration (TGA) and is currently on track to supply the remaining data over the next two weeks. Once approved, the Australian Technical Advisory Group on Immunisations (ATAGI) will advise the government on timing the rollout.
Current data suggests a clear advantage to immunising children against COVID-19, including protecting them from severe complications associated with the Delta variant, and helping to minimise the spread of the virus amongst the more vulnerable in the community.
Follow this link to read the full article:
COVID vaccines for 5 to 11 year old’s are inching closer. Here’s what we know so far
Advice on returning Australian children
ATAGI have provided COVID-19 vaccination advice for children aged 12 years and over returning to Australia from overseas.
In an effort to keep families together, New South Wales, Victoria and the Australian Capital Territory have agreed to apply an exemption for those Australians aged 12–17 to arrive from overseas who are not fully vaccinated (have received 2 doses of a TGA recognised COVID-19 vaccine, adhering to the recommended dosing interval).
Affected children will be required to undertake a test within 24 hours of arrival into Australia and quarantine at home for 7 days. A second test will be required on day 5 prior to completion of quarantine. They may attend school after completing 7 days home quarantine. Additionally, 12–17 year olds not fully vaccinated will not be allowed to visit other high risk settings such as disability facilities, aged-care residential facilities and hospitals until 14 days after arrival.
बयान को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें:
Returning Australian children
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
Novavax has completed the rolling regulatory submission to the U.K Medicines and Healthcare products Regulatory Agency (MHRA) for authorization of the first protein-based COVID-19 vaccine.
The NVX-CoV2373 vaccine is engineered from the genetic sequence of the first strain of SARS-CoV-2. Using Novavax recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein and is formulated with Novavax patented saponin-based Matrix-M ™ adjuvant to stimulate high levels of neutralizing antibodies.
Clinical data from Phase 3 trials included over 15,000 participants and demonstrated that NVX-CoV2373 elicited a strong immune response with an overall efficacy of 89.7% as well as a favourable safety and tolerability profile.
पूरा लेख पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
World Polio Day 2021 highlights progress and ongoing commitment to end polio everywhere
There’s been incredible progress in the efforts to eradicate polio everywhere. Currently, 5 out of 6 WHO regions are certified free of wild polio.
Despite the progress, there is still a way to go and although it is rare, cases of wild or vaccine-derived strain can become emergent in polio-free regions, including those countries that have not seen cases of polio for decades.
This demonstrates the importance of ensuring that every child is protected through immunisation. A fully immunised population is protected against both vaccine-derived and wild poliovirus.
पूरा लेख पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें:
World Polio Day 2021 highlights progress and ongoing commitment to end polio everywhere